Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 307 of the 310 references it cites were found in a registry or an index.
Abstract
Neurodegeneration is a chronic progressive loss of neuronal cells leading to deterioration of central nervous system (CNS) functionality. It has been shown that neuroinflammation precedes neurodegeneration in various neurodegenerative diseases. Matrix metalloproteinases (MMPs), a protein family of zinc‐containing endopeptidases, are essential in (neuro)inflammation and might be involved in neurodegeneration. Although MMPs are indispensable for physiological development and functioning of the organism, they are often referred to as double‐edged swords due to their ability to also inflict substantial damage in various pathological conditions. MMP activity is strictly controlled, and its dysregulation leads to a variety of pathologies. Investigation of their potential use as therapeutic targets requires a better understanding of their contributions to the development of neurodegenerative diseases. Here, we review MMPs and their roles in neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and multiple sclerosis (MS). We also discuss MMP inhibition as a possible therapeutic strategy to treat neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MMP-1, cleaves the structural connective tissue components collagen type I, II and II, and is detected only at low levels under physiological conditions, but can be abnormally high in several age-associated pathologies”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the association between MMP-1 and ROS and the significance of these interactions in degenerative disease etiology is well established”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“Additionally, ALS is associated with protein inclusions composed mostly of transactive response DNAbinding protein 43 (TDP-43) in the cytoplasm in the affected areas of the brain and spinal cord [232].”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575 · cited 1×
“of MMPs), catalytic domain (holds the Zn ion), hinge region (connecting sequences), and C-terminal hemopexinlike domain (required for substrate and TIMP recognition) [6] (Figure 1).”
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“When triggered by various immunological stimuli, microglia morphologically transform into ameboid cells and start to proliferate and secrete inflammatory mediators [109, 110].”
BackgroundMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“However, it is speculated that initial neurotoxic insult to dopaminergic neurons results in the release of certain factors that activate microglia and convert them from beneficial into harmful [121].”
BackgroundNagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“Besides aging, the most prominent genetic risk factor for developing late onset AD is the presence of apolipoprotein E ε4 allele (APOE ε4) in the genome [173].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“Aβ deposits are typically surrounded by dystrophic neurites, reactive astrocytes, and activated microglia, forming densecore plaques in the brain parenchyma [158].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“Studies on postmortem tissue of PD patients, as well as in vivo imaging, revealed astrogliosis, overactivation of microglia, and infiltration of peripheral immune cells into brain regions affected by PD [191–195].”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 1×
“and/or contribute to aging and to some of the age-related diseases, such as AD [137, 138].”
BackgroundReactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947 · cited 1×
“This could be explained by specific susceptibility of dopaminergic neurons to oxidative stress due to the presence of tyrosine hydroxylase and monoamine oxidase, which are ROS-generating enzymes, as well as excessive production of easily oxidized cytosolic dopamine [217, 218].”
BackgroundAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · cited 1×
“1 million in 2025 [40].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“Furthermore, there are large numbers of patients with other neurodegenerative diseases, includingAD, PD,ALS,HD,MS, and frontotemporal dementia [41].”
BackgroundOxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Yu, Q., & Stamenkovic, I. (2000) · PubMed · Cited by 2,203
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 1×
“Other evidence for the involvement of active microglia in triggering neurodegeneration of dopaminergic neurons in the substantia nigra comes from studies on injection of lipopolysaccharide (LPS) systemically or directly in the substantia nigra [213–215].”
BackgroundFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Two of the most prominent characteristics of aging are immunosenescence (deterioration of immune responses) and inflammaging (presence of chronic low grade inflammation) [124, 125].”
BackgroundNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · cited 1×
“Hirsch and Hunot described early microglial activation after MPTP injection, followed by later neuronal cell death and infiltration of T cells and astrogliosis [189].”
BackgroundNeurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“Furthermore, it has been shown that besides the established direct neurotoxic effect [166], Aβ can exert indirect proinflammatory effects via microglial activation, which results in secretion of NO, TNFα, and superoxides [167, 168].”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869 · cited 1×
“Some authors point to the role of an imbalance in ROS formation and cellular antioxidant activity in AD [163].”
BackgroundAgeing as a Risk Factor for Disease
Niccoli, T., & Partridge, L. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.024 · Cited by 1,831 · cited 1×
“However, it is not yet clear how aging acts on the development of neurodegenerative diseases and other age-related diseases [123].”
BackgroundYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751 · cited 1×
“Additionally, mutations in parkin, PINK1, and LRRK2 have been identified as possible causes of other cases of familial PD [186, 187].”
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635 · cited 2×
“Worldwide, 47 million people are living with AD and other dementias, including more than 5 million in the United States alone [39], where the number is expected to rise to 7.”
BackgroundSatake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 2×
“The group of Zlokovic reported that, both in transgenic mice and in humans, APOE ε4 leads to BBB breakdown by activating the proinflammatory cyclophilin A (CypA)/MMP-9 pathway in brain pericytes, which are important components of the neurovascular unit and guardians of BBB integrity [61, 174].”
BackgroundZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 2×
“In PD patients, active microglia have been observed in most of the regions with Lewy bodies, and in vivo imaging revealed microglial activation throughout the different stages of the disease, indicating chronic microglial activation [196].”
BackgroundProcessing of tumour necrosis factor-α precursor by metalloproteinases
Gearing, A. J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., et al. (1994) · Nature · doi:10.1038/370555a0 · Cited by 1,194
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Amyloid Precursor Protein Trafficking, Processing, and Function
Thinakaran, G., & Koo, E. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800019200 · Cited by 1,141 · cited 2×
“It has been shown that some of themembers of the metalloproteinase family, including the ADAM (a disintegrin andmetalloproteinase) proteinsADAM-17 (also called tumor necrosis factor-α-converting enzyme or TACE), ADAM-9 and ADAM-10, can cleave APP at the α-secretase cleaving site [150].”
BackgroundStructural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J. I., Van Nostrand, W. E., & Smith, S. O. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1799 · Cited by 1,111
Debris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111 · cited 1×
“It has been shown that microglia are involved in neuron survival [112], neurogenesis [113], facilitation of brain repair via guidance of stem-cellmigration to the site of inflammation or injury [114], and clearance of cell debris [115].”
BackgroundCerebral amyloid angiopathy. A critical review.
Vinters, H. V. (1987) · Stroke · doi:10.1161/01.str.18.2.311 · Cited by 1,071 · cited 1×
“Besides, deposition of Aβ occurs in the cerebral vasculature in both cerebral amyloid angiopathy (CAA) and in 90% of patients with AD [149].”
BackgroundIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“Interestingly, clustering of activated microglia around Aβ aggregates has been observed even before the development of AD symptoms [169–171].”
BackgroundTansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045 · cited 1×
“Thus, some hypotheses propose that neuroinflammation could play a pivotal role in promotion and aggravation of the disease [188–190].”
BackgroundInnate immunity in the central nervous system
Ransohoff, R. M., & Brown, M. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58644 · Cited by 1,034 · cited 1×
“They also produce different inflammatory mediators, including cytokines, chemokines, and complement components [119].”
BackgroundProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Microglia as neuroprotective, immunocompetent cells of the CNS
Streit, W. J. (2002) · Glia · doi:10.1002/glia.10154 · Cited by 919 · cited 1×
“It has been shown that microglia are involved in neuron survival [112], neurogenesis [113], facilitation of brain repair via guidance of stem-cellmigration to the site of inflammation or injury [114], and clearance of cell debris [115].”
BackgroundThe impact of the extracellular matrix on inflammation
Sorokin, L. (2010) · Nature Reviews Immunology · doi:10.1038/nri2852 · Cited by 912 · cited 1×
“Additionally, MMPs play an active role in immune processes by cleaving various molecules, including growth factors, death receptors, chemokines, and cytokines [9, 10].”
BackgroundArend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891 · cited 1×
“This has been shown in different peripheral chronic diseases, such as atherosclerosis and rheumatoid arthritis [25, 26], and neuroinflammatory diseases, such as cerebral ischemia, stroke, and bacterial meningitis [27].”
BackgroundKim, W.-G., Mohney, R. P., Wilson, B., Jeohn, G.-H., Liu, B., & Hong, J.-S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 878
Matrix Metalloproteinases and Cardiovascular Disease
Dollery, C. M., McEwan, J. R., & Henney, A. M. (1995) · Circulation Research · doi:10.1161/01.res.77.5.863 · Cited by 864
Chiò, A., Logroscino, G., Traynor, B. J., Collins, J., Simeone, J. C., Goldstein, L. A., & White, L. A. (2013) · Neuroepidemiology · doi:10.1159/000351153 · Cited by 862
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832 · cited 5×
“metzincins, a family of Zn-dependent, Ca-containing endopeptidases (24 members in mammals) [1].”
BackgroundInfluentialSelf-citationNewby, A. C. (2005) · Physiological Reviews · doi:10.1152/physrev.00048.2003 · Cited by 817 · cited 1×
“This has been shown in different peripheral chronic diseases, such as atherosclerosis and rheumatoid arthritis [25, 26], and neuroinflammatory diseases, such as cerebral ischemia, stroke, and bacterial meningitis [27].”
BackgroundBlum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Causes, consequences, and reversal of immune system aging
Montecino-Rodriguez, E., Berent-Maoz, B., & Dorshkind, K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64096 · Cited by 793 · cited 1×
“Two of the most prominent characteristics of aging are immunosenescence (deterioration of immune responses) and inflammaging (presence of chronic low grade inflammation) [124, 125].”
BackgroundImamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“Microglial activation was also found in other PD models [203] and in other brain regions in PD patients, including putamen, hippocampus, transentorhinal cortex, cingulate cortex, and temporal cortex [204].”
ResultNon‐motor symptoms in Parkinson’s disease
Poewe, W. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02056.x · Cited by 782
Biological role of matrix metalloproteinases: a critical balance
Löffek, S., Schilling, O., & Franzke, C.-W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00146510 · Cited by 756 · cited 1×
“MMPs are modulated on several levels: transcriptional activation, removal of the prodomain, interaction with ECM components, and inhibition by endogenous inhibitors such as tissue inhibitors of metalloproteinases (TIMPs) [19].”
BackgroundTurner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease
Marsden, C. D., & Obeso, J. A. (1994) · Brain · doi:10.1093/brain/117.4.877 · Cited by 712 · cited 1×
“Thus, due to dopaminergic neuron cell death, one of the clear manifestations of the disease is loss of control over movements, resting tremor, bradykinesia, and rigidity [183].”
BackgroundGenetics of Parkinson disease: paradigm shifts and future prospects
Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 707
Dystrophic microglia in the aging human brain
Streit, W. J., Sammons, N. W., Kuhns, A. J., & Sparks, D. L. (2004) · Glia · doi:10.1002/glia.10319 · Cited by 705 · cited 1×
“Physiological aging is associated with a progressive increase in the number of activated microglial cells in the brain and spinal cord [126–128] accompanied by transition from normal microglial morphology to microglial dystrophy [129].”
BackgroundGao, H., Jiang, J., Wilson, B., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 687 · cited 1×
“Other evidence for the involvement of active microglia in triggering neurodegeneration of dopaminergic neurons in the substantia nigra comes from studies on injection of lipopolysaccharide (LPS) systemically or directly in the substantia nigra [213–215].”
BackgroundFunctional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
Obeso, J. A., Rodríguez-Oroz, M. C., Benitez-Temino, B., Blesa, F. J., Guridi, J., Marin, C., & Rodriguez, M. (2008) · Movement Disorders · doi:10.1002/mds.22062 · Cited by 663
Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.08.154 · Cited by 656
Control of matrix metalloproteinase catalytic activity
Ra, H.-J., & Parks, W. C. (2007) · Matrix Biology · doi:10.1016/j.matbio.2007.07.001 · Cited by 647 · cited 1×
“The thiol group of a cysteine residue in the N-terminal prodomain binds to and blocks the active-site Zn atom; activation occurs when the thiol group is blocked or removed [8].”
BackgroundWu, D.-C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937239100 · Cited by 633
Production of tumor necrosis factor-alpha by microglia and astrocytes in culture
Sawada, M., Kondo, N., Suzumura, A., & Marunouchi, T. (1989) · Brain Research · doi:10.1016/0006-8993(89)90078-4 · Cited by 631 · cited 1×
“Nevertheless, when overactive, microglia can inflict severe damage to the brain by excessive production of molecules such as MMPs, proinflammatory cytokines and chemokines, and cytotoxic molecules such as ROS and nitric oxide (NO) [116–118].”
BackgroundMechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628 · cited 1×
“The new hypothesis that emerged resembles the previously proposedmechanism for the other neurodegenerative disorders: perpetuated inflammation leads to triggering of neurodegenerative processes [250].”
BackgroundInflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624 · cited 1×
“Microglial activation was also found in other PD models [203] and in other brain regions in PD patients, including putamen, hippocampus, transentorhinal cortex, cingulate cortex, and temporal cortex [204].”
ResultProduction of superoxide anions by a CNS macrophage, the microglia
Colton, C. A., & Gilbert, D. L. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80305-8 · Cited by 614 · cited 1×
“Nevertheless, when overactive, microglia can inflict severe damage to the brain by excessive production of molecules such as MMPs, proinflammatory cytokines and chemokines, and cytotoxic molecules such as ROS and nitric oxide (NO) [116–118].”
BackgroundNitric oxide synthase and neuronal vulnerability in parkinson's disease
Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., & Hirsch, E. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00578-1 · Cited by 595 · cited 1×
“Active microglia are known to secrete inflammatory mediators, and accordingly, increased proinflammatory cytokine levels were increased in the substantia nigra [206, 207] and CSF in PD [208].”
BackgroundMatrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Tu, S., Okamoto, S.-I., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 576
Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567
Lippa, C. F., Fujiwara, H., Mann, D. M. A., Giasson, B., Baba, M., Schmidt, M. L., Nee, L. E., O'Connell, B., Pollen, D. A., St. George-Hyslop, P., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65722-7 · Cited by 533 · cited 1×
“Interestingly, inclusions similar to Lewy bodies were found in 22% of cases of familial AD, and they occur also in dementia with Lewy bodies (DLB) and in multiple system atrophy (MSA) [181].”
BackgroundCandelario-Jalil, E., Yang, Y., & Rosenberg, G. A. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.025 · Cited by 527 · cited 2×
“Alternatively, several MMPs have been shown to activate proinflammatory cytokines and free radicals, which enhances inflammation and subsequently induces disruption of the CNS barriers [27, 34, 35].”
BackgroundAdvanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., & Münch, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.016 · Cited by 524 · cited 1×
“Activation of the receptor for AGE (RAGE) leads to release of proinflammatory cytokines and free radicals, further contributing to inflammatory processes [135].”
BackgroundThe Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6301-6_19 · Cited by 510 · cited 1×
“Active microglia are known to secrete inflammatory mediators, and accordingly, increased proinflammatory cytokine levels were increased in the substantia nigra [206, 207] and CSF in PD [208].”
BackgroundInflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
Knott, C., Stern, G., & Wilkin, G. P. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0914 · Cited by 503
Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory
Nagy, V., Bozdagi, O., Matynia, A., Balcerzyk, M., Okulski, P., Dzwonek, J., Costa, R. M., Silva, A. J., Kaczmarek, L., & Huntley, G. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4359-05.2006 · Cited by 499
(1973) · BMJ · doi:10.1136/bmj.2.5863.432 · Cited by 488
Martindale, D., Hackam, A., Wieczorek, A., Ellerby, L., Wellington, C., McCutcheon, K., Singaraja, R., Kazemi-Esfarjani, P., Devon, R., Kim, S. U., et al. (1998) · Nature Genetics · doi:10.1038/ng0298-150 · Cited by 485 · cited 1×
“While the exact role of Htt is not clear yet, it has been speculated that proteolysis of mutant Htt participates in the pathology [274].”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 1×
“involved in alteration of α-synuclein protein conformation, thus contributing to aggregation, Lewy body formation, and microglial activation [227].”
BackgroundOkamoto, T., Akaike, T., Sawa, T., Miyamoto, Y., van der Vliet, A., & Maeda, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102417200 · Cited by 468
Farace, C., Melguizo, C., Asara, Y., Álvarez, P., Prados, J. C., Tolu, P., Delogu, G., Aránega, A., & Madeddu, R. (2011) · Cited by 464
Braak, H., Sastre, M., & Del Tredici, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0244-3 · Cited by 462
Migration and differentiation of neural precursor cells can be directed by microglia
Aarum, J., Sandberg, K., Haeberlein, S. L. B., & Persson, M. A. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237050100 · Cited by 454 · cited 1×
“It has been shown that microglia are involved in neuron survival [112], neurogenesis [113], facilitation of brain repair via guidance of stem-cellmigration to the site of inflammation or injury [114], and clearance of cell debris [115].”
BackgroundD'ortho, M., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L., & Murphy, G. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00751.x · Cited by 443 · cited 1×
“For example, several MMPs can activate tumor necrosis factor (TNF) [11–15] and transforming growth factorbeta (TGF-β) [16], while other MMPs degrade interleukin1β (IL-1β) [17].”
BackgroundWijesekera, L. C., & Nigel Leigh, P. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-3 · Cited by 442
Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration
LIU, B., GAO, H., WANG, J., JEOHN, G., COOPER, C. L., & HONG, J. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04077.x · Cited by 425 · cited 1×
“Nevertheless, when overactive, microglia can inflict severe damage to the brain by excessive production of molecules such as MMPs, proinflammatory cytokines and chemokines, and cytotoxic molecules such as ROS and nitric oxide (NO) [116–118].”
BackgroundMultiple roles for MMPs and TIMPs in cerebral ischemia
Cunningham, L. A., Wetzel, M., & Rosenberg, G. A. (2005) · Glia · doi:10.1002/glia.20169 · Cited by 411 · cited 1×
“Compromise of CNS barrier integrity due to activation of MMPs has been observed in cerebral ischemia, traumatic brain injury (TBI), and other diseases associated with neuroinflammation [37].”
BackgroundCicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
How do immune cells overcome the blood-brain barrier in multiple sclerosis?
Larochelle, C., Alvarez, J. I., & Prat, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.066 · Cited by 405 · cited 1×
“The leukocyte infiltration further aggravates BBB breakdown, as shown in in vitro studies [267].”
BackgroundMicroglia instruct subventricular zone neurogenesis
Walton, N. M., Sutter, B. M., Laywell, E. D., Levkoff, L. H., Kearns, S. M., Marshall, G. P., Scheffler, B., & Steindler, D. A. (2006) · Glia · doi:10.1002/glia.20419 · Cited by 403 · cited 1×
“It has been shown that microglia are involved in neuron survival [112], neurogenesis [113], facilitation of brain repair via guidance of stem-cellmigration to the site of inflammation or injury [114], and clearance of cell debris [115].”
BackgroundMcGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400 · cited 1×
“This hypothesis is supported by postmortem studies describing progressive dopaminergic neuronal degeneration in humans and monkeys treated with MPTP for 10 years [65, 221].”
Reimagining Alzheimer's Disease—An Age-Based Hypothesis
Herrup, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-10.2010 · Cited by 396 · cited 1×
“These factors include genetics, nutrition, psychosocial influences, and exposure to toxic compounds [122].”
BackgroundHerrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392
Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041584.x · Cited by 390 · cited 1×
“Other evidence for the involvement of active microglia in triggering neurodegeneration of dopaminergic neurons in the substantia nigra comes from studies on injection of lipopolysaccharide (LPS) systemically or directly in the substantia nigra [213–215].”
BackgroundDegradation of Interleukin 1β by Matrix Metalloproteinases
Ito, A., Mukaiyama, A., Itoh, Y., Nagase, H., Thøgersen, I. B., Enghild, J. J., Sasaguri, Y., & Mori, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14657 · Cited by 389 · cited 1×
“For example, several MMPs can activate tumor necrosis factor (TNF) [11–15] and transforming growth factorbeta (TGF-β) [16], while other MMPs degrade interleukin1β (IL-1β) [17].”
BackgroundMatrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke
Lakhan, S. E., Kirchgessner, A., Tepper, D., & Leonard, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00032 · Cited by 384 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Cauwe, B., Van den Steen, P. E., & Opdenakker, G. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701340019 · Cited by 381 · cited 1×
“Additionally, MMPs play an active role in immune processes by cleaving various molecules, including growth factors, death receptors, chemokines, and cytokines [9, 10].”
BackgroundMatrix metalloproteinases and TIMPs
Woessner, J. F., & Nagase, H. (2000) · Medical Entomology and Zoology · Cited by 380
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380
The worldwide prevalence of multiple sclerosis
Pugliatti, M., Sotgiu, S., & Rosati, G. (2002) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(02)00036-7 · Cited by 370 · cited 1×
“approximately 400,000 in the US alone, and MS is twice as common in women as in men [245].”
BackgroundPerivascular Spaces and the Two Steps to Neuroinflammation
Owens, T., Bechmann, I., & Engelhardt, B. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818f9ca8 · Cited by 353 · cited 1×
“, proinflammatory cytokines) [106, 107].”
Conde, J. R., & Streit, W. J. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000202887.22082.63 · Cited by 344 · cited 3×
“It has been shown that aged microglia secrete IL1β [130] and increase MHC class II expression [131].”
BackgroundGijbels, K., Galardy, R. E., & Steinman, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117578 · Cited by 339 · cited 7×
“Moreover, in another study on a transgenic mouse model of AD, it was reported that inhibition of MMPs with GM6001 reduced the oxidative stress associated with CAA [86].”
BackgroundInfluentialSwarup, V., Phaneuf, D., Dupré, N., Petri, S., Strong, M., Kriz, J., & Julien, J.-P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111313 · Cited by 338
Critical Role for Microglial NADPH Oxidase in Rotenone-Induced Degeneration of Dopaminergic Neurons
Gao, H.-M., Liu, B., & Hong, J.-S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06181.2003 · Cited by 337 · cited 1×
“Furthermore, MMP-3 activated microglia produce superoxide, known to be involved in facilitation of dopaminergic neuronal cell death in vitro [222, 223] and in vivo [224].”
BackgroundPott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · cited 1×
“It has been speculated that prolonged overactivation of microglia and production of proinflammatory cytokines could lead to neuronal degeneration in PD [207, 211].”
BackgroundGlial cells and inflammation in parkinson's disease: A role in neurodegeneration?
Hirsch, E. C., Hunot, S., Damier, P., & Faucheux, B. (1998) · Annals of Neurology · doi:10.1002/ana.410440717 · Cited by 334
Disruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334 · cited 4×
“Besides the occurrence of the leakage, the BBB also becomes activated, meaning that cells making up the BBB, including endothelial cells, astrocytes, and potentially pericytes, start expressing and secreting various factors involved in the recruitment and functioning of leukocytes [258].”
BackgroundInfluentialBackstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
Neuronal Matrix Metalloproteinase-9 Is a Determinant of Selective Neurodegeneration
Kaplan, A., Spiller, K. J., Towne, C., Kanning, K. C., Choe, G. T., Geber, A., Akay, T., Aebischer, P., & Henderson, C. E. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.009 · Cited by 306 · cited 2×
“, diminishingMMP9 function by genetic, viral, or pharmacological intervention was shown to prolong survival in a SOD1 mouse model of ALS [244].”
BackgroundGao, H.-M., Liu, B., Zhang, W., & Hong, J.-S. (2003) · The FASEB Journal · doi:10.1096/fj.03-0109fje · Cited by 306
Harris, J. O., Frank, J. A., Patronas, N., McFarlin, D. E., & McFarland, H. F. (1991) · Annals of Neurology · doi:10.1002/ana.410290515 · Cited by 303 · cited 1×
“Nevertheless, BBB dysfunction is a temporary event, although recurrence is highly possible [256].”
BackgroundVaughan, D. W., & Peters, A. (1974) · Journal of Neurocytology · doi:10.1007/bf01098730 · Cited by 301 · cited 1×
“Physiological aging is associated with a progressive increase in the number of activated microglial cells in the brain and spinal cord [126–128] accompanied by transition from normal microglial morphology to microglial dystrophy [129].”
BackgroundMMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke
Chaturvedi, M., & Kaczmarek, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8538-z · Cited by 296
Qin, L., Liu, Y., Cooper, C., Liu, B., Wilson, B., & Hong, J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01210.x · Cited by 292 · cited 1×
“Furthermore, it has been shown that besides the established direct neurotoxic effect [166], Aβ can exert indirect proinflammatory effects via microglial activation, which results in secretion of NO, TNFα, and superoxides [167, 168].”
BackgroundLeppert, D., Waubant, E., Bürk, M. R., Oksenberg, J. R., & Hauser, S. L. (1996) · Annals of Neurology · doi:10.1002/ana.410400606 · Cited by 291 · cited 1×
“It is known that in MS, various brain and immune cells can secrete MMPs, thus contributing to the BBB breakdown [260, 261].”
BackgroundMaeda, A., & Sobel, R. A. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00005 · Cited by 291 · cited 1×
“Another group confirmed this finding and also showed expression of MMP3 in endothelial cells, MMP-1, MMP-2, MMP-3 and MMP-9 in macrophages, and to a lesser extent in astrocytes, around active and necrotic lesions [80].”
ResultMeighan, S. E., Meighan, P. C., Choudhury, P., Davis, C. J., Olson, M. L., Zornes, P. A., Wright, J. W., & Harding, J. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03565.x · Cited by 285 · cited 1×
“Notably, another study showed that MMP-3, by remodeling the ECM, is crucial for synaptic plasticity and learning [48].”
BackgroundWhite, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284 · cited 2×
“As reported forMMP-9,MMP-3 candegradeAβ [47, 50, 176].”
BackgroundAmyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J., & Tsai, L.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4305-10.2010 · Cited by 281 · cited 1×
“Therefore, other proposed mechanisms and manifestations of the disease should also be taken into account [162].”
BackgroundGijbels, K., Masure, S., Carton, H., & Opdenakker, G. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90192-n · Cited by 281
Rosenberg, G. A., Dencoff, J. E., Correa, N., Reiners, M., & Ford, C. C. (1996) · Neurology · doi:10.1212/wnl.46.6.1626 · Cited by 278 · cited 1×
“Similarly, association of MMP-9 with the disruption of the BBB was also reported in MRI studies [297].”
BackgroundMatrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes
Oh, L. Y. S., Larsen, P. H., Krekoski, C. A., Edwards, D. R., Donovan, F., Werb, Z., & Yong, V. W. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-19-08464.1999 · Cited by 267
Synaptic circuit remodelling by matrix metalloproteinases in health and disease
Huntley, G. W. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3320 · Cited by 267
Kook, S.-Y., Hong, H. S., Moon, M., Ha, C. M., Chang, S., & Mook-Jung, I. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6102-11.2012 · Cited by 265
Zecca, L., Zucca, F. A., Wilms, H., & Sulzer, D. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.009 · Cited by 264 · cited 7×
“It has been shown that damaged dopaminergic neurons can activate microglia by releasing 𝛼-synuclein [219] and neuromelanin, causing them to produce ROS [220].”
BackgroundInfluentialDubois, B., Masure, S., Hurtenbach, U., Paemen, L., Heremans, H., van den Oord, J., Sciot, R., Meinhardt, T., Hämmerling, G., Opdenakker, G., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6886 · Cited by 262
Immune aging, dysmetabolism, and inflammation in neurological diseases
Deleidi, M., Jäggle, M., & Rubino, G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00172 · Cited by 260 · cited 1×
“Lowlevel systemic inflammation during aging has also been linked to the presence of active microglia and increased proinflammatory cytokines levels in the brain [132–134].”
BackgroundMatrix Metalloproteinases Contribute to Brain Damage in Experimental Pneumococcal Meningitis
Leib, S. L., Leppert, D., Clements, J., & Täuber, M. G. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.615-620.2000 · Cited by 259 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Kim, Y. S., Kim, S. S., Cho, J. J., Choi, D. H., Hwang, O., Shin, D. H., Chun, H. S., Beal, M. F., & Joh, T. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4346-04.2005 · Cited by 258 · cited 2×
“The activated microglia release proinflammatory cytokines, such as TNF, that lead to neuronal cell death [64].”
BackgroundRozovsky, I., Finch, C. E., & Morgan, T. E. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00169-3 · Cited by 254 · cited 1×
“Physiological aging is associated with a progressive increase in the number of activated microglial cells in the brain and spinal cord [126–128] accompanied by transition from normal microglial morphology to microglial dystrophy [129].”
BackgroundTrojanowski, J. Q., & Lee, V. M.-Y. (1998) · Archives of Neurology · doi:10.1001/archneur.55.2.151 · Cited by 254
Cuzner, M. L., Gveric, D., Strand, C., Loughlin, A. J., Paemen, L., Opdenakker, G., & Newcombe, J. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199612000-00002 · Cited by 251
Leppert, D. (1998) · Brain · doi:10.1093/brain/121.12.2327 · Cited by 251
Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S., & Overall, C. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305862101 · Cited by 244 · cited 1×
“For example, several MMPs can activate tumor necrosis factor (TNF) [11–15] and transforming growth factorbeta (TGF-β) [16], while other MMPs degrade interleukin1β (IL-1β) [17].”
BackgroundFleur, M. L., Underwood, J. L., Rappolee, D. A., & Werb, Z. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2311 · Cited by 240 · cited 1×
“Additionally, MMP-activated axonal degeneration was hardly observed in peripheral nervous system, possibly due to the presence of resilient ECM and higher TIMPs expression [271].”
BackgroundWinkler, E. A., Sengillo, J. D., Sagare, A. P., Zhao, Z., Ma, Q., Zuniga, E., Wang, Y., Zhong, Z., Sullivan, J. S., Griffin, J. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401595111 · Cited by 238 · cited 1×
“Since BSCB disruption in ALS [237–239] is accompanied by downregulation of mRNA for tight junction proteins [240], Miyazaki et al.”
BackgroundProteolytic Cleavage of Extracellular Secreted α-Synuclein via Matrix Metalloproteinases
Sung, J. Y., Park, S. M., Lee, C.-H., Um, J. W., Lee, H. J., Kim, J., Oh, Y. J., Lee, S.-T., Paik, S. R., & Chung, K. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503341200 · Cited by 238
Non-steroidal anti-inflammatory drugs in Parkinson's disease
Esposito, E., Di Matteo, V., Benigno, A., Pierucci, M., Crescimanno, G., & Di Giovanni, G. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.008 · Cited by 234 · cited 1×
“Other evidence for the role of microglia in PD comes from studies using anti-inflammatory drugs to inhibit microglial activation, which was protective against neurodegeneration induced by MPTP or 6-OHDA [205].”
BackgroundMicroglial Expression of MHC Class II Increases in Normal Aging of Nonhuman Primates
Sheffield, L. G., & Berman, N. E. J. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00168-1 · Cited by 234
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
Waubant, E., Goodkin, D. E., Gee, L., Bacchetti, P., Sloan, R., Stewart, T., Andersson, P.-B., Stabler, G., & Miller, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1397 · Cited by 234 · cited 1×
“Also, by univariant analysis they found that an increase in MMP-9 and a decrease in TIMP-1 levels preceded the appearance of new lesions [263].”
BackgroundExtracellular matrix degradation by metalloproteinases and central nervous system diseases
Lukes, A., Mun-Bryce, S., Lukes, M., & Rosenberg, G. A. (1999) · Molecular Neurobiology · doi:10.1007/bf02821717 · Cited by 230
Gurney, K. J., Estrada, E. Y., & Rosenberg, G. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.006 · Cited by 229
Baker, D., Butler, D., Scallon, B. J., O'Neill, J. K., Turk, J. L., & Feldmann, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240916 · Cited by 229 · cited 2×
“So far, no molecular mechanism has been identified to explain how MMP inhibition ameliorates MS disease symptoms, but it is speculated that broad-spectrum MMP inhibition inhibits transmigration of immune cells into the CNS via the BBB.Thatwould result in reduced demyelination and reduced levels of TNF through inhibiti…”
BackgroundChandler, S., Cossins, J., Lury, J., & Wells, G. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1677 · Cited by 226
Ince (1998) · doi:10.1046/j.1365-2990.1998.00108.x · Cited by 224 · cited 1×
“Some other neurodegenerative diseases share similar etiology, such as progressive lateral sclerosis (PLS), progressive muscular atrophy (PMA), ALS dementia, and ALS frontal lobe dementia [229].”
BackgroundIgG Reactivity in the Spinal Cord and Motor Cortex in Amyotrophic Lateral Sclerosis
Engelhardt, J. I., & Appel, S. H. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530110068019 · Cited by 221 · cited 1×
“Since BSCB disruption in ALS [237–239] is accompanied by downregulation of mRNA for tight junction proteins [240], Miyazaki et al.”
Background6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218 · cited 1×
“and dopaminergic neurodegeneration [225, 226].”
Neuroinflammation in the living brain of Parkinson's disease
Ouchi, Y., Yagi, S., Yokokura, M., & Sakamoto, M. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70814-4 · Cited by 209 · cited 1×
“Studies on postmortem tissue of PD patients, as well as in vivo imaging, revealed astrogliosis, overactivation of microglia, and infiltration of peripheral immune cells into brain regions affected by PD [191–195].”
BackgroundMatrix Metalloproteinase-9 Controls NMDA Receptor Surface Diffusion through Integrin β1 Signaling
Michaluk, P., Mikasova, L., Groc, L., Frischknecht, R., Choquet, D., & Kaczmarek, L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5346-08.2009 · Cited by 206
Clements, J. M., Cossins, J. A., Wells, G. M. A., Corkill, D. J., Helfrich, K., Wood, L. M., Pigott, R., Stabler, G., Ward, G. A., Gearing, A. J. H., et al. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00210-x · Cited by 205
Barcia, C., Ros, C. M., Annese, V, Gómez, A., Ros-Bernal, F., Aguado-Llera, D., Martínez-Pagán, M. E., de Pablos, V, Fernandez-Villalba, E., & Herrero, M. T. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.17 · Cited by 203 · cited 2×
“Active microglia are known to secrete inflammatory mediators, and accordingly, increased proinflammatory cytokine levels were increased in the substantia nigra [206, 207] and CSF in PD [208].”
BackgroundYe, S.-M., & Johnson, R. W. (2001) · Neuroimmunomodulation · doi:10.1159/000049025 · Cited by 203
Distinct neuroinflammatory profile in post-mortem human Huntington's disease
Silvestroni, A., Faull, R. L. M., Strand, A. D., & Möller, T. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832e34ee · Cited by 203 · cited 1×
“Analysis of deceased patients with HD revealed an increase in MMP-9 in comparison to controls, as well as upregulation of cytokine levels (IL-6, IL-8) in cortex and cerebellum [78].”
BackgroundKim, Y. S., Choi, D. H., Block, M. L., Lorenzl, S., Yang, L., Kim, Y. J., Sugama, S., Cho, B. P., Hwang, O., Browne, S. E., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-5865com · Cited by 199
The Role of Microglia and Matrix Metalloproteinases Involvement in Neuroinflammation and Gliomas
Könnecke, H., & Bechmann, I. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/914104 · Cited by 199 · cited 1×
“Beneficial roles of MMPs have also been noted in MS [253].”
BackgroundSerum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis
Lee, M. A., Palace, J., Stabler, G., Ford, J., Gearing, A., & Miller, K. (1999) · Brain · doi:10.1093/brain/122.2.191 · Cited by 199
Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis
Miyazaki, K., Ohta, Y., Nagai, M., Morimoto, N., Kurata, T., Takehisa, Y., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22594 · Cited by 197 · cited 1×
“speculated that MMP-9 is involved in barrier disruption [241].”
BackgroundSchubert-Unkmeir, A., Konrad, C., Slanina, H., Czapek, F., Hebling, S., & Frosch, M. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000874 · Cited by 192
DESCHAMPS, A., & SPINALE, F. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.10.004 · Cited by 189
Miller, J. P., Holcomb, J., Al-Ramahi, I., de Haro, M., Gafni, J., Zhang, N., Kim, E., Sanhueza, M., Torcassi, C., Kwak, S., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.06.021 · Cited by 186 · cited 3×
“Besides caspases and calpains acting as proteases in HD, it seems that MMPs also have a distinctive role in cleavage of Htt. Miller et al. have shown that knocking down MMP-10, MMP-14, and MMP-23 in cultured striatal cells expressing mutant Htt diminishes toxicity.”
BackgroundInfluentialTNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183
Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases
Brkic, M., Balusu, S., Van Wonterghem, E., Gorlé, N., Benilova, I., Kremer, A., Van Hove, I., Moons, L., De Strooper, B., Kanazir, S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0006-15.2015 · Cited by 182
Self-citationBjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180 · cited 2×
“proposed MMP-9 and TIMP-1 as biomarkers of AD, next to T-tau, P-tau, Aβ 1–42, and white matter lesions [52].”
BackgroundGraeber, M. B., Kösel, S., Egensperger, R., Banati, R. B., Müller, U., Bise, K., Hoff, P., Möller, H. J., Fujisawa, K., & Mehraein, P. (1997) · neurogenetics · doi:10.1007/s100480050011 · Cited by 177 · cited 1×
“Also considered hallmarks of AD are neurofibrillary tangles (NFT), intercellular deposits of a hyperphosphorylated form of Tau protein [159].”
BackgroundEnhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions
Cossins, J. A., Clements, J. M., Ford, J., Miller, K. M., Pigott, R., Vos, W., Van Der Valk, P., & De Groot, C. J. A. (1997) · Acta Neuropathologica · doi:10.1007/s004010050754 · Cited by 176
A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor
Miyazaki, K., Hasegawa, M., Funahashi, K., & Umeda, M. (1993) · Nature · doi:10.1038/362839a0 · Cited by 175
Astrocytes as mediators of immune and inflammatory responses in the CNS.
Aschner, M. (1998) · PubMed · Cited by 169
Brain Under Surveillance: The Microglia Patrol
Fetler, L., & Amigorena, S. (2005) · Science · doi:10.1126/science.1114852 · Cited by 168 · cited 1×
“When triggered by various immunological stimuli, microglia morphologically transform into ameboid cells and start to proliferate and secrete inflammatory mediators [109, 110].”
BackgroundLorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. W., & Beal, M. F. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8019 · Cited by 167
Washington, R., Burton, J., Todd, R. F., Newman, W., Dragovic, L., & Dore‐Duffy, P. (1994) · Annals of Neurology · doi:10.1002/ana.410350114 · Cited by 167 · cited 1×
“Functional changes in the BBB were observed in postmortem brains of MS patients [257].”
BackgroundLindberg, R. L. P. (2001) · Brain · doi:10.1093/brain/124.9.1743 · Cited by 166 · cited 1×
“Data show involvement of MMPs in each of these processes [252–255].”
BackgroundChen, F., Ohashi, N., Li, W., Eckman, C., & Nguyen, J. H. (2009) · Hepatology · doi:10.1002/hep.23203 · Cited by 165
Lorenzl, S., Albers, D. S., LeWitt, P. A., Chirichigno, J. W., Hilgenberg, S. L., Cudkowicz, M. E., & Beal, M. F. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00398-2 · Cited by 164 · cited 1×
“found increased TIMP-1 and TIMP-2 levels in CSF of patients suffering from HD [276].”
BackgroundDeb, S., & Gottschall, P. E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66041641.x · Cited by 163
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis
Kieseier, B. (1998) · Brain · doi:10.1093/brain/121.1.159 · Cited by 163 · cited 1×
“showed that the increase in MMP-9 and MMP-7 expression in blood vessels and parenchyma strongly correlated with the peak of the disease [262].”
BackgroundIncreased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment
Bruno, M. A., Mufson, E. J., Wuu, J., & Cuello, A. C. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c22569 · Cited by 162 · cited 2×
“, no elevation of MMP-2 activity was observed in AD patients [53].”
BackgroundWoo, M., Park, J., Choi, I., Kim, W., & Kim, H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05430.x · Cited by 162
Walsh, S. R., Finn, D. P., & Dowd, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.005 · Cited by 160
Smith, M. E., van der Maesen, K., & Somera, F. P. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981001)54:1<68::aid-jnr8>3.0.co;2-f · Cited by 160
Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model
Chang, K., Wu, Y., Chen, Y., & Chen, C. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.09.011 · Cited by 156 · cited 1×
“Moreover, significantly elevated levels of MMP-9 were found in plasma of patients suffering from HD, as well as in the R6/2 mouse HDmodel [275].”
BackgroundDECREASED mRNA EXPRESSION OF TIGHT JUNCTION PROTEINS IN LUMBAR SPINAL CORDS OF PATIENTS WITH ALS
Henkel, J. S., Beers, D. R., Wen, S., Bowser, R., & Appel, S. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a41228 · Cited by 153 · cited 1×
“Since BSCB disruption in ALS [237–239] is accompanied by downregulation of mRNA for tight junction proteins [240], Miyazaki et al.”
BackgroundVandenbroucke, R. E., Dejonckheere, E., Hauwermeiren, F. V., Lodens, S., Rycke, R. M. D., Wonterghem, E. V., Staes, A., Gevaert, K., López-Otín, C., & Libert, C. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202100 · Cited by 152 · cited 1×
“MMP inhibitors yielded beneficial results in animal studies of lung inflammatory diseases [282], multiple sclerosis [265], meningitis [283–285], vascular dementia [52], stroke [286], acute cerebral ischemia [287, 288], and sepsis [1, 15, 289, 290].”
Self-citationMatrix Metalloproteinases and TlMPs
Woessner, J. F., & Nagase, H. (2000) · doi:10.1093/oso/9780198502685.001.0001 · Cited by 148
Overlap between neurodegenerative disorders
Armstrong, R. A., Lantos, P. L., & Cairns, N. J. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2005.00605.x · Cited by 146
Marracci, G., Jones, R. E., McKeon, G. P., & BOURDETTE, D. N. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00269-2 · Cited by 144 · cited 1×
“This effect was linked with reduced infiltration of T cells into the CNS, which led to speculation that α-lipoic acid could be inhibiting MMP-9 [298].”
BackgroundHewson, A. K., Smith, T., Leonard, J. P., & Cuzner, M. L. (1995) · Inflammation Research · doi:10.1007/bf01796266 · Cited by 144 · cited 18×
“There are several reports on the use of synthetic MMP inhibitors to ameliorate the symptoms of EAE, and protease inhibitors were used to treat EAE as early as 1982 [295].”
BackgroundResultInfluentialNewman, T. A. (2001) · Brain · doi:10.1093/brain/124.11.2203 · Cited by 143
Amyotrophic lateral sclerosis: A neurovascular disease
Garbuzova-Davis, S. N., Rodrigues, M. C. O., Hernandez‐Ontiveros, D. G., Louis, M. K., Willing, A. E., Borlongan, C. V., & Sanberg, P. R. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.049 · Cited by 142 · cited 2×
“MMPs are secreted upon inflammation, for example, by peripheral neutrophils, which thereby contribute to aggravation of the inflammation and disruption of the barriers [36].”
Background
Research works printed but not linked: 4
- 10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f · doi:10.1002/(sici)1097-4547(19981001)54:160;68::aid-jnr862;3.0.co;2-f
- 10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m · doi:10.1002/1531-8249(199912)46:660;860::aid-ana862;3.0.co;2-m
- Goldenberg M. M., 2012, Multiple sclerosis review, P & T, 37, 175
- 10.1523/JNEUROSCI.0967-12.2012 · DOI · Paper page
Cited by
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
“It has been shown that MMPs participate in a common pathway related to the pathological changes in CNS homeostasis, that is, the accumulation of pro-inflammatory molecules or aggregates of proteins and peptides, leading to the increased permeability of the CNS barrier and, therefore, to cell death [48].”
BackgroundInfluentialde Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Chinta, S. J., Woods, G., Demaria, M., Rane, A., Zou, Y., McQuade, A., Rajagopalan, S., Limbad, C., Madden, D. T., Campisi, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.092 · Cited by 530
“, 2010); SASP factors have been shown to disrupt tissue structure and function (Brkic et al., 2015).”
BackgroundThe vascular basement membrane in the healthy and pathological brain
Thomsen, M. S., Routhe, L. J., & Moos, T. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17722436 · Cited by 490
“MMPs, a family of zinc endopeptidases, are produced in a latent form and contain a pro-peptide responsible for maintaining the latent form of MMP and a hemopexin-like domain, which can be recognized by tissue inhibitor of metalloproteinases (TIMPs).(96) The activity of these protease systems is highly regulated and de…”
Background
Metadata
- Authors
- Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E.
- Affiliations
- Ghent University (BE)
- Corresponding author
- Vandenbroucke, Roosmarijn E.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 620581-620581
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4619970
- OpenAlex
- W2165521823
- Cited by
- 205
- References
- 310
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 19 · 2023: 12 · 2022: 24 · 2021: 36 · 2020: 28 · 2019: 13 · 2018: 24 · 2017: 22 · 2016: 8
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Science and Technological Development of the Republic of Serbia (ON173056)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- matrix metalloproteinases, neurodegenerative diseases, neuroinflammation, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, matrix metalloproteinase inhibition, therapeutic target
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Humans, Huntington Disease, Inflammation, Multiple Sclerosis, Parkinson Disease, Biomarkers, Gene Expression Regulation, Enzymologic, Neurodegenerative Diseases, Matrix Metalloproteinases, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.